Examples of using Kovaltry in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Kovaltry contains sodium.
How is Kovaltry used?
Other information about Kovaltry.
How Kovaltry is given.
Other medicines and Kovaltry.
Why is Kovaltry approved?
Kovaltry does not contain von Willebrand factor.
If you have any questions about Kovaltry and compatible separate filters, contact Bayer Pharma AG.
Kovaltry™ is a full-length recombinant Factor VIII product.
It is recommended that every time that you use Kovaltry, you note down name and batch number of the product.
How Kovaltry is prepared for adminsitration.
Do not increase the dose of Kovaltry to control your bleeding without checking with your doctor.
How Kovaltry is prepared for administration.
The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII.
Kovaltry is available as a powder and solvent used to make a solution for injection.
What Kovaltry looks like and contents of the pack.
Kovaltry 1000 IU contains(1,000 IU/ 2.5 mL) 400 IU octocog alfa per mL after reconstitution.
In March 2016, Kovaltry™ was approved by the U.S. Food and Drug Administration(FDA) and the Japanese Ministry of Health, Labour and Welfare MHLW.
Kovaltry is a medicine that contains the active substance human recombinant coagulation factor VIII, also called octocog alfa.
It is strongly recommended that every time Kovaltry is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.
How much Kovaltry you should use and how often you should use it depends on many factors such as.
Kovaltry is provided as a powder and solvent for solution for injection and is a dry, white to slightly yellow powder or cake.
Kovaltry is not likely to affect the fertility in male or female patients, as the active substance is naturally occurring in the body.
Kovaltry has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups.
Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A an inherited bleeding disorder caused by lack of a clotting protein called factor VIII.
The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Kovaltry is an unmodified full-length recombinant factor VIII product, that in clinical trials has demonstrated control of bleeds, and protection from bleeds in hemophilia A patients when used prophylactically two or three times per week.
In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.
Kovaltry 250 IU powder and solvent for solution for injection Kovaltry 500 IU powder and solvent for solution for injection Kovaltry 1000 IU powder and solvent for solution for injection Kovaltry 2000 IU powder and solvent for solution for injection Kovaltry 3000 IU powder and solvent for solution for injection.